KNTC1 and non-small cell lung carcinoma: Developing KNTC1 inhibitors or combining it with potential chemical agents such as paclitaxel may be a promising treatment strategy for advanced NSCLC, and may also be used to against the resistance of NSCLC patients to paclitaxel.